Blink Reminders and Meibomian Gland Loss in Digital Screen Users

Inclusion Criteria: * Participants aged 18 to 40 years. * Intensive digital screen users, defined as an average screen time of ≥4 hours per day for at least 3 days per week. * Ocular Surface Disease Index (OSDI) score ≥13 (indicating mild to severe symptoms). * Non-invasive tear break-up time (NIBUT) ≤10 seconds measured by infrared meibography. * Presence of visible Meibomian glands on baseline meibography, allowing for quantitative analysis. * Technical ability to install and operate the BlinkEasy software on their primary digital device. Exclusion Criteria: * Active ocular disease, including infections, corneal ulcers, or acute conjunctivitis. * History of ocular surgery (e.g., refractive surgery, cataract extraction) or significant ocular injury. * Use of topical ophthalmic medications affecting the ocular surface (e.g., steroids, glaucoma medications, or cyclosporine) within the last 3 months. * Active use of contact lenses that cannot be suspended for the duration of the 12-week study period. * Systemic conditions known to affect the ocular surface (e.g., Sjögren's syndrome, Rheumatoid Arthritis). * Diagnosis of Diabetes Mellitus (Type 1 or Type 2).